Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02414347 · ClinicalTrials.gov registry record
F 18 T807 Tau PET Imaging of Alzheimer's Disease
A clinical trial of Alzheimer Disease, sponsored by Tammie L. S. Benzinger, MD, PhD.
- Recruiting
- Registry status
- 900
- Enrollment target
- 1
- Study location
NCT02414347: Recruiting study of Alzheimer Disease, sponsored by Tammie L. S. Benzinger, MD, PhD.
NCT02414347 is a study of Alzheimer Disease that is actively recruiting participants, run by Tammie L. S. Benzinger, MD, PhD. The registered enrollment target is 900 participants, below the 2,748-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02414347, a study of Alzheimer Disease, is actively recruiting participants, sponsored by Tammie L. S. Benzinger, MD, PhD.
- RECRUITING
- Registry status
- 900 participants
- Enrollment target
- 1
- Study location
Study Summary
A single-center, open-label baseline controlled imaging study designed to assess whether brain tau fibril uptake of flortaucipir as measured by PET correlates with cognitive status of individuals with and without brain tau fibrils.
Primary Outcome
Employing statistical parametric mapping (SPM), a voxel-based analytic measure in order to quantify and co-localize the imaging patterns from the multiple imaging datasets in this study.
Conditions Studied
Interventions
- DRUG F 18 T807
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2014-10-23 |
| Est. Completion | 2024-12 |
What NCT02414347 shows while recruiting
NCT02414347 is an observational study that tracks outcomes without assigning an intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, below the 2,748-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which F 18 T807 is the first listed.
NCT02414347 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT02414347 about?
NCT02414347 is a clinical study titled "F 18 T807 Tau PET Imaging of Alzheimer's Disease". A single-center, open-label baseline controlled imaging study designed to assess whether brain tau fibril uptake of flortaucipir as measured by PET correlates with cognitive status of individuals with and without brain tau fibrils.
What is the current status of trial NCT02414347?
This trial is currently recruiting. The enrollment target is 900 participants. The study started on 2014-10-23. Estimated completion is 2024-12.
What conditions does trial NCT02414347 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT02414347?
The interventions under investigation include: F 18 T807 (DRUG).
Who is sponsoring clinical trial NCT02414347?
This trial is sponsored by Tammie L. S. Benzinger, MD, PhD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02414347 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02414347's enrollment target sits among peer trials
900 35th of 306 higher than 272 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT02960022 · 900 participants · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
- NCT03932786 · 900 participants
Studying Health Outcomes After Treatment in Patients With Retinoblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI